This disclosure describes a fentanyl hapten, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten and the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten and the fentanyl hapten-carrier conjugate. The fentanyl hapten-carrier conjugate may be used, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl and its analogues. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

The presently-disclosed subject matter generally relates to methods for treating a subject with Alzheimer's Disease, microhemorrhages, and neurological deficits. The presently-disclosed subject matter also relates to methods for treating a subject with Alzheimer's Disease, microhemorrhages, and neurological deficits with a composition that increases epoxyeicosatrienoic acids. The presently-disclosed subject matter further relates to a method of treating or preventing Alzheimer's Disease comprising administering an agent that increases vascular LRP1 expression.

The presently-disclosed subject matter generally relates to methods for treating a subject with Alzheimer's Disease, microhemorrhages, and neurological deficits. The presently-disclosed subject matter also relates to methods for treating a subject with Alzheimer's Disease, microhemorrhages, and neurological deficits with a composition that increases epoxyeicosatrienoic acids. The presently-disclosed subject matter further relates to a method of treating or preventing Alzheimer's Disease comprising administering an agent that increases vascular LRP1 expression.

Provided herein are methods and compounds for targeted autophagy.

Provided herein are methods and compounds for targeted autophagy.

A method of attenuating opioid induced cardio and/or respiratory depression in a subject in need thereof includes administering to the subject an amount of a composition comprising a nitroxide compound effective to attenuate the opioid induced cardio and/or respiratory depression.

A method of attenuating opioid induced cardio and/or respiratory depression in a subject in need thereof includes administering to the subject an amount of a composition comprising a nitroxide compound effective to attenuate the opioid induced cardio and/or respiratory depression.

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

##STR00001##

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

##STR00001##

An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I): ##STR00001##
wherein ring A, ring B, R1 to R6, l, m, and n are as defined in the specification.